Fighting infections
before they occur

Live Biotherapeutic Products (LBPs) are a class of biological therapeutics containing live microorganisms, such as bacteria or yeast, that are used to prevent, treat, or cure diseases in humans. They differ from probiotics as they are developed and regulated as medicinal products with specific therapeutic purposes. LBPs exclude vaccines, fecal microbiota transplants, and gene therapy agents and may involve either natural or genetically engineered microbes. Read more in our blog article.

Microbiome therapies are treatments designed to enhance and restore the balance of microbial communities within the human body to promote health and treat diseases. They encompass various approaches, including prebiotics, probiotics, fecal microbiota transplantation (FMT), live biotherapeutics, and postbiotics, each targeting specific aspects of microbial composition and function.

Our initial focus is on decolonizing gram-negative multidrug resistant bacteria from the gut of patients. This asymptomatic gut colonization is the most critical risk factor for subsequent infection inclusing sepsis, (recurring) urinary tract infections (UTI) and pneumonia. However, our research indicates potential applications in several other conditions that are caused by a dysregulated microbiome.

Multidrug resistance (MDR) is a major health problem according to WHO because it renders antibiotics ineffective, making infections harder or impossible to treat, leading to higher mortality rates (+5 Mio deaths), prolonged illnesses, increased healthcare costs (> 3 Trillion), and limited treatment options.

Unlike broad-spectrum approaches that use large consortia of bacteria, we focus on a very limited number of well-characterized bacterial strains. This enables more precise targeting and potentially fewer side effects in clinical testing, as well as accelerated scalability and drug approval.

We are in the early stages of development. Our technology has shown promising results in various preclinical studies and mouse models, and we are preparing for our first clinical trial.

Yes, we have filed various patents. We are continually expanding our IP portfolio as our research progresses.

We have secured several non-dilutive pre-seed fundings from the Helmholtz Association, DZIF, BMBF GoBio and others. We are currently preparing for our Seed/Series A funding round to support our upcoming clinical trial.

We aim to initiate our first Phase I/IIa clinical trial within the next timeframe, e.g., 12-18 months, which marks a critical step towards regulatory approval and investor attraction.

Yes, we are always looking for talented individuals passionate about microbiome research and drug development. Please check our website for current openings or feel free to reach out via our contact form.